



PRESS RELEASE

Sustained performance in Q1FY 2022-23

Mumbai, 09th August, 2022: During the first quarter of FY 2022-23, revenues of Indoco Remedies grew by 3.6 % at Rs. 394.9 crores, as against Rs.381.2 crores, same quarter last year. EBIDTA to net sales for the quarter is 18.1 % at Rs. 71.3 crores, compared to 22.8 % at Rs. 86.8 crores, same quarter last year. For the quarter, the Profit After Tax to net sales is 9.7 % at Rs. 38.5 crores, compared to 10.4 % at Rs. 39.6 crores, same quarter last year.

Commenting on the first quarter FY 2022-23 results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, “After a turbulent India Business performance of last year with highs & lows of COVID, I am happy to report that we have a steady performance in the Domestic Business and an excellent growth in the International Business”

For the quarter ended Jun’22, the financials are as under:

(Rs. in Crores)

Particulars	Apr’22- Jun’22	Jan’22- Mar’22	Apr’21- Jun’21	YoY Gw %
Net Revenues	394.9	400.3	381.2	3.6
EBIDTA	71.3	80.5	86.8	(17.9)
Operating Profit	65.3	79.1	76.9	(15.0)
Profit After Tax	38.5	40.4	39.6	(2.9)
EPS (Face value Rs. 2/-)	4.17	4.38	4.30	

About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 198 million Company, employs over 7000 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility in Hyderabad. The facilities have been approved by various Regulatory Authorities, including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 83 million prescriptions annually from over 3,00,000 doctors belonging to various specialties. Indoco has 8 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gyneacology, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM 69, Methycal, Homide, Cal-Aid, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:

Vilas V. Nagare

Mobile: 9820215745

E-mail: vilasn@indoco.com / corpcom@indoco.com